Brand-Name vs Compounded GLP-1 Medications

For two years, the case for compounded GLP-1 medication was simple arithmetic: roughly $99 a month against roughly $1,300. Two things have since changed that calculation — the FDA determined the shortages were over, and the manufacturers started selling direct at a fraction of list price. Here is where that leaves you.

The short version

Compounded GLP-1s were never approved by the FDA. They became widely available because federal law lets compounders make versions of drugs that appear on FDA's shortage list, and both semaglutide and tirzepatide sat on that list for years. FDA has since determined those shortages resolved, and the exemption went with them.

Compounding has not disappeared, but it now operates under narrower conditions. At the same time, Novo Nordisk and Eli Lilly launched direct self-pay pricing that brought FDA-approved medication down to $149–$299 a month. The savings that justified taking on an unevaluated product have largely evaporated.

What the FDA actually determined

This is worth getting precisely right, because a great deal of confident nonsense is written about it.

FDA states that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list. Compounders relying on shortage status therefore no longer have that basis. The timeline ran as follows:

• Tirzepatide. After a district court denied the plaintiffs' preliminary injunction motion on March 5, 2025 in Outsourcing Facilities Association v. FDA, the period of enforcement discretion for state-licensed pharmacies and physicians compounding under section 503A ended. For outsourcing facilities under 503B, FDA stated it did not intend to act on shortage-dependent violations until March 19, 2025.
• Semaglutide. The 503A enforcement discretion ran until April 22, 2025, or the district court's decision on the preliminary injunction motion, whichever came later. The court denied that motion on April 24, 2025, at which point the 503A period ended. For 503B outsourcing facilities, FDA stated it did not intend to act on shortage-dependent violations until May 22, 2025.

So why can you still buy compounded semaglutide?

Because the shortage exemption was never the only route. Section 503A permits a state-licensed pharmacy or physician to compound a drug for an individual patient based on receipt of a prescription. What it restricts is making copies of drugs you can already buy.

FDA considers a compounded product to be essentially a copy of a commercially available drug when it has the same active ingredient in the same, similar, or easily substitutable strength, and the commercial product can be used by the same route of administration. There is one exception, and it is the hinge on which this entire market now turns:

…unless a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient.

This is why you see so much emphasis on "personalised" and "custom" dosing in GLP-1 telehealth marketing. A documented clinical reason why a particular patient needs something the commercial product cannot provide is the basis on which the prescription is written.

FDA has also stated an enforcement position with a specific threshold: it does not intend to take action against a compounder for compounding an essentially-a-copy product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that product in a calendar month.

We cannot tell you how any individual provider satisfies these conditions. That is not visible from the outside, and no provider we reviewed names its compounding pharmacy — which makes it harder still.

The B12 combination question

Some compounded products combine semaglutide with vitamin B12. FDA has addressed this directly, stating it may consider such a combination essentially a copy of a commercially available drug when the products are used by the same route of administration and the amounts of each ingredient are within 10% of the strengths of the respective commercially available products.

If you have been told a semaglutide/B12 combination is meaningfully different from plain semaglutide, that is a claim worth asking your prescriber to explain in clinical terms.

What you are actually buying, either way

The price argument has mostly collapsed

This is the part most articles have not caught up with. The compounded market was built on a price gap that no longer exists at anything like its former size.

NovoCare Pharmacy, Novo Nordisk's direct channel, lists the Wegovy pill from $149/month and the injection pen from $199/month for new patients, with no membership fee. Meanwhile a compounded program advertising "$99 semaglutide" usually attaches a membership: at Mochi Health, $79/month on top, for a real total near $178.

For tirzepatide the gap is narrower still. LillyDirect lists Zepbound at $299/month for the 2.5 mg starting dose. Compounded tirzepatide at $199 plus a $79 membership comes to roughly $278. That is a $21 difference between an FDA-approved product and one that has not been evaluated.

Regulators have acted on the marketing

Separately from the shortage determinations, the FDA has been enforcing against how these products are sold. On March 3, 2026 it announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products on their websites — described as the second such group, following an earlier round reported at 25 letters.

The two primary violations cited were claims implying sameness with FDA-approved products, and obscuring product sourcing by branding compounded products with the telehealth firm's own name, implying that firm is the compounder.

We have written up the agency's full list of flagged claims as a checklist you can run against any provider's website — see GLP-1 marketing red flags. It is the single most useful consumer tool we found in this research.

What FDA has warned about

FDA has stated it is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. carrying false information on the product label. Separately, the agency has raised concerns about unapproved GLP-1 drugs used for weight loss.

Two practical implications. First, buying from an established provider with a real clinical relationship is materially different from buying peptides from an unregulated seller — "research use only" products are not medicines and should not be injected. Second, if your provider will not tell you which pharmacy compounds your medication, you have no way to check anything about it.

How to decide

We are not going to tell you which to choose; that is a conversation for you and your prescriber. But these are the questions that actually separate the two options:

• Have you priced the approved product recently? Manufacturer self-pay pricing is new enough that many people are working from 2024 numbers.
• What dose will you end up on? Starting-dose pricing is where compounded looks best. Ask what month six costs.
• Have you tested your insurance? A covered copay beats every cash price in this article, and compounded medication is essentially never covered.
• Do you know who is compounding it? If the answer is no, you cannot evaluate the thing you are injecting.
• How much does regulatory evaluation matter to you? It is a real difference in what you are buying, and reasonable people weigh it differently.

The bottom line

Compounded GLP-1s filled a genuine gap when brand-name medication was unaffordable and often unavailable. That gap has narrowed on both counts. The shortages are over by FDA's determination, the legal basis for large-scale compounding went with them, and manufacturer pricing has brought approved medication to within roughly $20 to $50 a month of the compounded alternative for most people at starting doses.

If you are currently on compounded medication and it is working, nothing here is a reason to stop — talk to your prescriber before changing anything. If you are choosing now, run the numbers on the approved product before assuming compounded is the cheaper answer. It frequently is not.